Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Company Drug PIC

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Fineline Cube Sep 11, 2026
Company Drug PIC

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Fineline Cube Sep 11, 2026
Company Drug PIC

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Fineline Cube Sep 11, 2026
Company Deals PIC

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Fineline Cube Sep 11, 2026
Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Fineline Cube Sep 11, 2026
Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Fineline Cube Sep 11, 2026
Company Deals

Organon Inks Deal to Acquire Dermavant, Bolstering Dermatology Portfolio with Vtama Cream

Fineline Cube Sep 19, 2024

US healthcare company Organon (NYSE: OGN) has announced a definitive agreement to acquire Dermavant, a...

Company Drug

MSD’s Keytruda Secures FDA Approval for First-Line Mesothelioma Treatment in Combination with Chemotherapy

Fineline Cube Sep 19, 2024

Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced that the US Food and...

Company Drug

AstraZeneca’s Fasenra Secures FDA Nod for EGPA Treatment, Strengthening Rare Disease Portfolio

Fineline Cube Sep 19, 2024

UK pharmaceutical giant AstraZeneca (NASDAQ: AZN, LON: AZN) has announced that the US Food and...

Company Deals

Fidson Healthcare Partners with Chinese Entities to Establish Drug Plant in Nigeria

Fineline Cube Sep 19, 2024

Nigeria-based pharmaceutical manufacturer Fidson Healthcare Plc has entered into a strategic partnership with Jiansu Aidea...

Company Deals

MGI Tech Joins Forces with Dasa to Enhance Precision Medicine in Brazil Through Advanced Genomic Sequencing

Fineline Cube Sep 19, 2024

MGI Tech Co., Ltd, a leading gene sequencing company based in China, has announced a...

Company Drug

AstraZeneca’s Tagrisso Achieves Milestones in Phase III LAURA Study for EGFR-mutated NSCLC at ESMO 2024

Fineline Cube Sep 19, 2024

Global pharmaceutical company AstraZeneca (AZ, NASDAQ: AZN, LON: AZN) has reported updated results from the...

Company Drug

Keymed Biosciences’ Stapokibart Receives First Prescription in China for IL-4Rα Targeting Therapy

Fineline Cube Sep 19, 2024

China-based biotech company Keymed Biosciences Inc. (HKG: 2162) has reached a significant milestone with its...

Company Drug

Adagene’s ADG126 Shows Promising Results in Phase Ib/II Study for MSS CRC at ESMO 2024

Fineline Cube Sep 19, 2024

Adagene Inc. (NASDAQ: ADAG), a biopharmaceutical company dedicated to the discovery and development of innovative...

Company Drug

Transcenta’s Osemitamab Combo Therapy Shows Promising Results in G/GEJ Cancer Treatment at ESMO 2024

Fineline Cube Sep 19, 2024

Transcenta Holdings Ltd (HKG: 6628), a leading biopharmaceutical company, has announced updated positive results from...

Company Drug

I-Mab’s Plonmarlimab Receives Breakthrough Therapy Designation in China for R/R MAS Treatment

Fineline Cube Sep 19, 2024

China-based biopharmaceutical company I-Mab (NASDAQ: IMAB) has announced that its proprietary human granulocyte-macrophage colony-stimulating factor...

Company Deals

Altamira Therapeutics and Nuance Pharma Expand Bentrio’s Reach in Asia

Fineline Cube Sep 18, 2024

Swiss pharmaceutical firm Altamira Therapeutics Ltd (NASDAQ: CYTO) and its Chinese partner Nuance Pharma have...

Company Drug

MSD and Daiichi Sankyo’s Patritumab Deruxtecan Achieves Milestone in Phase III Lung Cancer Trial

Fineline Cube Sep 18, 2024

Global healthcare leaders Merck, Sharp & Dohme Inc.(MSD; NYSE: MRK), known as MSD outside the...

Company Drug

GSK’s Blenrep-BorDex Combo Earns Breakthrough Therapy Designation in China for Multiple Myeloma

Fineline Cube Sep 18, 2024

The UK-based pharmaceutical colossus, GSK (LON: GSK, NYSE: GSK), has secured a Breakthrough Therapy Designation...

Company Drug

AstraZeneca’s Imfinzi-Imjudo Combo Sets New Longevity Benchmark in Liver Cancer Treatment

Fineline Cube Sep 18, 2024

UK pharmaceutical giant AstraZeneca (NASDAQ: AZN, LON: AZN) has achieved a significant milestone with its...

Company Drug

BeiGene’s Tislelizumab Receives Israeli Nod for Oesophageal Cancer Treatment

Fineline Cube Sep 18, 2024

China-based biotech firm BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has been granted market...

Company Drug

Abbisko Therapeutics’ FGFR4 Inhibitor Irpagratinib Shows Positive Phase I Results at ESMO Congress

Fineline Cube Sep 18, 2024

Shanghai-based biotech firm Abbisko Therapeutics Co., Ltd (HKG: 2256) has presented updates on its innovative...

Company Drug

Alphamab Oncology’s JSKN003 ADC Achieves Positive Safety and Efficacy Outcomes in Phase I Studies

Fineline Cube Sep 18, 2024

Alphamab Oncology (HKG: 9966), a leading player in the oncology space, has reported encouraging results...

Company Drug

CStone Pharmaceuticals’ Sugemalimab Shows Promising Long-Term Survival Data at ESMO 202

Fineline Cube Sep 18, 2024

CStone Pharmaceuticals (HKG: 2616), a biopharmaceutical company based in China, has presented long-term treatment and...

Company Drug

Ascletis Pharma Initiates Phase I Trials for Monthly Subcutaneous and Daily Oral Obesity Treatment ASC30 in the US

Fineline Cube Sep 18, 2024

Ascletis Pharma Inc. (HKG: 1672), a biopharmaceutical company based in China, has announced the dosing...

Company

Harbour BioMed’s 2024 H1 Revenues Decline Amid R&D Optimization and Pipeline Advancements

Fineline Cube Sep 18, 2024

Harbour BioMed (HKG: 2142), a biopharmaceutical company with operations in the United States, the Netherlands,...

Posts pagination

1 … 349 350 351 … 719

Recent updates

  • Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption
  • BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis
  • Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China
  • China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories
  • Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Company Drug

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Policy / Regulatory

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.